Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ryanair Holdings plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Ryanair Holdings plc trades at $64.3 (market cap $31.76B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.53% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RYAAY | |
|---|---|---|
Market Cap | $39.89B | $31.76B |
Sector | Health | Industrials |
52-Week High | $491.22 | $73.82 |
52-Week Low | $278.09 | $53.24 |
Enterprise Value | $38.15B | $29.42B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
RYAAY trades at $64.65, up 0.78% today, with a bullish technical signal and strong fundamentals including a 13.9 P/E ratio and 25.37% ROE. Recent earnings beat expectations in three of the last four quarters, and June 2026 traffic grew 7% year-over-year. The company maintains a debt-free balance sheet after repaying its final bond in May 2026, enhancing financial flexibility amid sector volatility.
Outlook remains positive with analyst consensus at 62.5% buy ratings, supported by robust operational execution and 80% fuel hedging for 2027. Key risks include rising operating costs, geopolitical tensions affecting fuel prices, and regulatory scrutiny over seating policies. The stock's valuation appears reasonable relative to earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
